2. Signaling Pathways
  3. Cell Cycle/DNA Damage
  4. Polo-like Kinase (PLK)

Polo-like Kinase (PLK)

Polo-like Kinase (PLK)

Related Products

PDF 0.57 MB

Polo-like Kinases (PLKs) are a group of highly conserved serine/threonine protein kinases that play a key role in processes such as cell division and checkpoint regulation of mitosis. In mammals, five PLKs (PLK 1-5) encompass diverse roles in centrosome dynamics, spindle formation, intra S-phase and G2/M checkpoints, and DNA damage response.

PLKs are characterized by their Polo-box domain, which mediates protein interactions. They are additionally controlled by phosphorylation, proteolysis, and transcription, depending on the biological context. PLKs are now recognized to link cell division to developmental processes and to function in differentiated cells.

Polo-like Kinase (PLK) Isoform Specific Products:

Polo-like Kinase (PLK) Isoform Comparison
Cat. No. Product Name Effect Purity Chemical Structure
  • HY-132135
    (1E)-CFI-400437 dihydrochloride
    		Inhibitor 98.89%
    (1E)-CFI-400437 dihydrochloride is a potent PLK4 (IC50= 0.6 nM) inhibitor and selective against other members of the PLK family (>10 μM). (1E)-CFI-400437 dihydrochloride inhibits Aurora A, Aurora B, VEGFR2/KDR/Flk-1 and FLT-3 with IC50s of 0.37, 0.21, 0.48, and 0.18 μM, respectively. Antiproliferative activity.
    (1E)-CFI-400437 dihydrochloride
  • HY-12134
    Poloxin
    		Inhibitor 98.01%
    Poloxin is a non-ATP competitive Polo-like Kinase 1 (PLK1) inhibitor that targets the polo-box domain, with an IC50 of appr 4.8 μM.
    Poloxin
  • HY-147298
    Plogosertib
    		Inhibitor 99.95%
    Plogosertib (CYC140) is a selective, potent, and orally active ATP-competitive PLK1 inhibitor (IC50: 3 nM). Plogosertib is an anti-cancer agent with anti-proliferative activity. Plogosertib can be used in the research of several tumors, including esophageal, gastric, leukemia, non–small cell lung cancer, ovarian, and squamous cell cancers.
    Plogosertib
  • HY-13994
    Mps1-IN-2
    		Inhibitor 98.04%
    Mps1-IN-2 is a potent, selective and ATP-competitive dual Mps1/Plk1 inhibitor, with an IC50 and a Kd of 145 nM and 12 nM for Mps1 and a Kd of 61 nM for Plk1.
    Mps1-IN-2
  • HY-15158
    SBE13 Hydrochloride
    		Inhibitor 99.66%
    SBE13 Hydrochloride is a potent and selective Plk1 inhibitor, with an IC50 of 200 pM; SBE13 Hydrochloride poorly inhibits Plk2 (IC50>66 μM) or Plk3 (IC50=875 nM).
    SBE13 Hydrochloride
  • HY-15160B
    TAK-960 dihydrochloride
    		Inhibitor 99.19%
    TAK-960 dihydrochloride is an orally available, selective inhibitor of polo-like kinase 1 (PLK1), with an IC50 of 0.8 nM. TAK-960 dihydrochloride also shows inhibitory activities against PLK2 and PLK3, with IC50s of 16.9 and 50.2 nM, respectively. TAK-960 dihydrochloride inhibits proliferation of multiple cancer cell lines and exhibits significant efficacy against multiple tumor xenografts.
    TAK-960 dihydrochloride
  • HY-134775
    PLK4-IN-1
    		Inhibitor 99.94%
    PLK4-IN-1 (Example A6) is a PLK4 inhibitor, with an IC50 of ≤ 0.1 μM.
    PLK4-IN-1
  • HY-13647
    HMN-176
    		Inhibitor 98.84%
    HMN-176 is a stilbene derivative which inhibits mitosis, interfering with polo-like kinase-1 (plk1), without significant effect on tubulin polymerization. 
    HMN-176
  • HY-15159
    Cyclapolin 9
    		Inhibitor 99.16%
    Cyclapolin 9 is a potent, selective and ATP-competitive polo-like kinase 1 (PLK1) inhibitor with an IC50 of 500 nM. Cyclapolin 9 is inactive against other kinases.
    Cyclapolin 9
  • HY-N8692
    Dihydrobaicalein
    		Inhibitor 99.94%
    Dihydrobaicalein is a PLK1 Inhibitor with an IC50 of 6.3 μM. Dihydrobaicalein also inhibits VRK2 and PLK2. Dihydrobaicalein is a natural product that can be isolated from Scutellaria scandens.
    Dihydrobaicalein
  • HY-149324
    SP27
    		Degrader 98.87%
    SP27 is a PROTAC that can selective degrades PLK4, with a DC50 of 19.5 nM. SP27 can be used for the research of breast cancer.
    SP27
  • HY-151971
    Aurora Kinases-IN-3
    		Inhibitor 98.47%
    Aurora Kinases-IN-3 (Compound 15a) is an orally active AURKB inhibitor that elicits an AURKB-suppressive activity by disrupting the mitotic localization of AURKB, rather than inhibiting its phosphorylation of H3 at Ser10.
    Aurora Kinases-IN-3
  • HY-110002
    LFM-A13
    		Inhibitor
    LFM-A13 is a potent BTK, JAK2, PLK inhibitor, inhibits recombinant BTK, Plx1 and PLK3 with IC50s of 2.5 μM, 10 μM and 61 μM. LFM-A13 has antiproliferative activity and anticancer activity. LFM-A13 can be used in cancer-related research
    LFM-A13
  • HY-15158A
    SBE13
    		Inhibitor
    SBE13 is a potent and selective Plk1 inhibitor, with an IC50 of 200 pM; SBE13 poorly inhibits Plk2 (IC50>66 μM) or Plk3 (IC50=875 nM).
    SBE13
  • HY-77195
    Poloxime
    		Inhibitor
    Poloxime, a hydrolysis product of poloxin, is a non-ATP-competitive Plk1 inhibitor, with moderate Plk1 inhibitory activity.
    Poloxime
  • HY-12137A
    Volasertib trihydrochloride
    		Inhibitor
    Volasertib (BI 6727) trihydrochloride is an orally active, highly potent and ATP-competitive Polo-like kinase 1 (PLK1) inhibitor with an IC50 of 0.87 nM. Volasertib trihydrochloride inhibits PLK2 and PLK3 with IC50s of 5 and 56 nM, respectively. Volasertib trihydrochloride induces mitotic arrest and apoptosis. Volasertib trihydrochloride, a dihydropteridinone derivative, shows marked antitumor activity in multiple cancer models.
    Volasertib trihydrochloride
  • HY-126249
    AAPK-25
    		Inhibitor 98.31%
    AAPK-25 is a potent and selective Aurora/PLK dual inhibitor with anti-tumor activity, which can cause mitotic delay and arrest cells in a prometaphase, reflecting by the biomarker histone H3Ser10 phosphorylation and followed by a surge in apoptosis. AAPK-25 targets Aurora-A, -B, and -C with Kd values ranging from 23-289 nM, as well as PLK-1, -2, and -3 with Kd values ranging from 55-456 nM.
    AAPK-25
  • HY-18651
    (E/Z)-Rigosertib sodium
    Rigosertib (ON-01910) is a biochemical reagent that can be used as a biological material or organic compound for life science related research.
    (E/Z)-Rigosertib sodium
  • HY-112395
    BTO-1
    		Inhibitor
    BTO-1 is a Polo-like kinase (Plk) inhibitor. BTO-1 is primarily used for phosphorylation and dephosphorylation applications.
    BTO-1
  • HY-155377
    PLK1/p38γ-IN-1
    		Inhibitor
    PLK1/p38γ-IN-1(compound 14) is a multitarget inhibitors ofPLK1andp38γ. PLK1/p38γ-IN-1inhibits the growth of human hepatocellular carcinoma and hepatoblastoma cells in vitro.
    PLK1/p38γ-IN-1
Cat. No. Product Name / Synonyms Species Source
Cat. No. Product Name / Synonyms Application Reactivity
Polo-like Kinase (PLK) Isoform Comparison

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.